• Grail at JPM: Looking Forward to Study Readouts, Prepped for Scale

    Jan 15 | Diagnostics World | Grail presented for the first time at the 42rd Annual J.P. Morgan Healthcare conference today, and Bob Ragusa, CEO, took the stage. Grail was divested from Illumina and became an independent, publicly traded company in June 2024. But while the company structure has changed significantly in 2024, the mission has not, Ragusa said: detecting cancer early, when it can be cured. More

  • Mayo Clinic, NVIDIA Announce Collaboration on Digital Twins at J.P. Morgan Healthcare Conference

    Jan 13 | Diagnostics World | Among the many partnerships and technical announcements made by NVIDIA during the company's Monday morning presentation at the 43rd Annual J.P. Morgan Healthcare Conference, NVIDIA focused several on innovation within the healthcare and life sciences industry. More

  • Beyond Breath: Researchers Look to Leverage VOCs from Skin, Urine, and More

    Jan 09 | Diagnostics World | In the next phase of breath diagnostics, there is a promising area for future research: expanding upon the notion of “breath diagnostics” to leverage volatile organic compounds (VOCs) from elsewhere.  VOCs from urine could be used to detect prostate cancer, for example. If looked at carefully with the right AI tools, leveraging VOCs could lead to compelling healthcare solutions down the road. More

  • Chronic Fatigue Syndrome and Long COVID: Quest for Clues in Muscle Tissue

    Jan 08 | Diagnostics World | An international team of researchers hope to identify molecular and cellular level changes in muscle tissue that can be used to help diagnose and treat chronic fatigue syndrome (CFS) and long COVID. The quest is being pursued from both the physiological and electrical perspectives to better understand the muscle damage seen with the debilitating and still-mysterious conditions that share some striking similarities. More

  • Trendspotting: Predictions for Diagnostics World in 2025

    Jan 07 | Diagnostics World | 2024 was full of innovative ideas and achievements. We spoke with industry experts and leaders about what to expect in the new year. Here are the full predictions and trends, including more information on the impact of AI/ML, spatial biology, antimicrobial resistance, and more. More

  • Top Stories from 2024: FDA Regulations, Babson Diagnostics, Thermo Fisher, CDx, More

    Jan 03 | Diagnostics World | 2024 was a packed year for diagnostics, starting with the FDA’s final rule amending the agency’s regulations to clarify in vitro diagnostics (IVDs). Companion diagnostics (CDx) also made great strides. Plus: Babson Diagnostics has a new blood testing that does what Theranos claimed to do. Here are the top stories of Diagnostic World News and thoughts from industry leaders. More

  • PathAI Develops Algorithms for Breast Cancer Biomarkers, Smartphone App for Cardiopulmonary Assessment, More

    Dec 27 | Diagnostics World | PathAI launches the AIM-IHC Breast Panel; electronRx plans purpleDx, a cardiopulmonary assessment app; and more. More

  • Follow the Money: First-in-Class ADCs for Underserved Cancers, Insulin Delivery System, More

    Dec 23 | Diagnostics World | Adcendo plans to advance ADC programs; Beta Bionics to expand iLet Bionic Pancreas; and more. More

  • Circulating DNA Accurately Predicts for Prostate Cancer Prognosis

    Dec 17 | Diagnostics World | Sepsis ImmunoScore, the first FDA-authorized AI diagnostic for sepsis, has high accuracy for the diagnosis of sepsis and for prediction of key adverse patient outcomes, reports a paper published last week in the New England Journal of Medicine AI. In the paper, the authors write that the test showed both diagnostic and prognostic power. More

  • Sepsis AI Tool Validated for Both Diagnostic, Prognostic Use

    Dec 12 | Diagnostics World | Sepsis ImmunoScore, the first FDA-authorized AI diagnostic for sepsis, has high accuracy for the diagnosis of sepsis and for prediction of key adverse patient outcomes, reports a paper published last week in the New England Journal of Medicine AI. In the paper, the authors write that the test showed both diagnostic and prognostic power. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more